Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size

REFERENCES

• Berry , D. A. ( 2006 ). A guide to drug discovery: Bayesian clinical trials . Nature Reviews Drug Discovery 5 : 27 – 36 .
   PubMed Web of Science ®Google Scholar
• Brentjens , R. J. , Santos , E. , Nikhamin , Y. , Yeh , R. , Matsushita , M. , La Perle , K. , Quintás-Cardama , A. , Larson , S. M. , Sadelain , M. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research 13(18 Pt 1):5426–5435.
   PubMed Web of Science ®Google Scholar
• Cheadle , E. J. , Gilham , D. E. , Thistlethwaite , F. C. , Radford , J. A. , Hawkins , R. E. ( 2005 ). Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells . British Journal of Haematology 129 ( 3 ): 322 – 332 .
   PubMed Web of Science ®Google Scholar
• Cheung , Y. K. , Chappel , R. ( 2000 ). Sequential designs for Phase I clinical trials with late-onset toxicities . Biometrics 56 ( 4 ): 1177 – 1182 .
   PubMed Web of Science ®Google Scholar
• Cooper , L. J. , Topp , M. S. , Serrano , L. M. , Gonzalez , S. , Chang , W. C. , Naranjo , A. , Wright , C. , Popplewell , L. , Raubitschek , A. , Forman , S. J. , Jensen , M. C. ( 2003 ). T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect . Blood 101 ( 4 ): 1637 – 1644 .
   PubMed Web of Science ®Google Scholar
• Cooper , L. J. , Al-Kadhimi , Z. , DiGiusto , D. , Kalos , M. , Colcher , D. , Raubitschek , A. , Forman , S. J. , Jensen , M. C. ( 2004 ). Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies . Blood Cells, Molecules and Diseases 33 ( 1 ): 83 – 89 .
   PubMed Web of Science ®Google Scholar
• Huang , X. , Biswas , S. , Oki , Y. , Issa , J. P. , Berry , D. A. ( 2007 ). A parallel Phase I/II clinical trial design for combination therapies . Biometrics 63 ( 2 ): 429 – 436 .
   PubMed Web of Science ®Google Scholar
• Ji , Y. , Li , Y. , Bekele , B. N. ( 2007 ). Dose-finding in oncology clinical trials based on toxicity probability intervals . Clinical Trials 4 : 235 – 244 .
   PubMed Web of Science ®Google Scholar
• June , C. H. ( 2007 ). Adoptive T cell therapy for cancer in the clinic . Journal of Clinical Investigation 117 ( 6 ): 1466 – 1476 .
   PubMed Web of Science ®Google Scholar
• Komanduri , K. V. , St John , L. S. , de Lima , M. , McMannis , J. , Rosinski , S. , McNiece , I. , Bryan , S. G. , Kaur , I. , Martin , S. , Wieder , E. D. , Worth , L. , Cooper , L. J. , Petropoulos , D. , Molldrem , J. J. , Champlin , R. E. , Shpall , E. J. ( 2007 ). Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing . Blood 110 ( 13 ): 4543 – 4551 .
   PubMed Web of Science ®Google Scholar
• Mazzatti , D. J. , White , A. , Forsey , R. J. , Powell , J. R. , Pawelec , G. ( 2007 ). Gene expression changes in long-term culture of T-cell clones: Genomic effects of chronic antigenic stress in aging and immunosenescence . Aging Cell 6 ( 2 ): 155 – 163 .
   PubMed Web of Science ®Google Scholar
• Morgan , R. A. , Dudley , M. E. , Wunderlich , J. R. , Hughes , M. S. , Yang , J. C. , Sherry , R. M. , Royal , R. E. , Topalian , S. L. , Kammula , U. S. , Restifo , N. P. , Zheng , Z. , Nahvi , A. , de Vries , C. R. , Rogers-Freezer , L. J. , Mavroukakis , S. A. , Rosenberg , S. A. ( 2006 ). Cancer regression in patients after transfer of genetically engineered lymphocytes . Science 314 ( 5796 ): 126 – 129 .
   PubMed Web of Science ®Google Scholar
• Numbenjapon , T. , Serrano , L. M. , Singh , H. , Kowolik , C. M. , Olivares , S. , Gonzalez , N. , Chang , W. C. , Forman , S. J. , Jensen , M. C. , Cooper , L. J. ( 2006 ). Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells . Leukemia 20 ( 10 ): 1889 – 1892 .
   PubMed Web of Science ®Google Scholar
• Numbenjapon , T. , Serrano , L. M. , Chang , W. C. , Forman , S. J. , Jensen , M. C. , Cooper , L. J. ( 2007 ). Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8 + T cells . Experimental Hematology 35 ( 7 ): 1083 – 1090 .
   PubMed Web of Science ®Google Scholar
• O'Quigley , J. , Pepe , M. , Fisher , L. ( 1990 ). Continual reassessment method: A practical design for Phase I clinical trials in cancer . Biometrics 46 ( 1 ): 33 – 48 .
   PubMed Web of Science ®Google Scholar
• Pawelec , G. , Rehbein , A. , Haehnel , K. , Merl , A. , Adibzadeh , M. ( 1997 ). Human T-cell clones in long-term culture as a model of immunosenescence . Immunology Reviews 160 : 31 – 42 .
   PubMed Web of Science ®Google Scholar
• Powell , D. J. , Jr., Dudley , M. E. , Robbins , P. F. , Rosenberg , S. A. ( 2005 ). Transition of late-stage effector T cells to CD27 + CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy . Blood 105 ( 1 ): 241 – 250 .
   PubMed Web of Science ®Google Scholar
• Rosenberg , S. A. , Restifo , N. P. , Yang , J. C. , Morgan , R. A. , Dudley , M. E. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nature Reviews Cancer 8(4):299–308.
   PubMed Web of Science ®Google Scholar
• Rosenberger , W. , Haines , L. ( 2002 ). Competing designs for Phase I clinical trials: A review . Statistics in Medicine 21 ( 18 ): 2757 – 2770 .
   PubMed Web of Science ®Google Scholar
• Rössig , C. , Pscherer , S. , Landmeier , S. , Altvater , B. , Jürgens , H. , Vormoor , J. ( 2005 ). Adoptive cellular immunotherapy with CD19-specific T cells . Klinische Padiatrie 217 ( 6 ): 351 – 356 .
   PubMed Web of Science ®Google Scholar
• Serrano , L. M. , Pfeiffer , T. , Olivares , S. , Numbenjapon , T. , Bennitt , J. , Kim , D. , Smith , D. , McNamara , G. , Al-Kadhimi , Z. , Rosenthal , J. , Forman , S. J. , Jensen , M. C. , Cooper , L. J. ( 2006 ). Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy . Blood 107 ( 7 ): 2643 – 2452 .
   PubMed Web of Science ®Google Scholar
• Shen , L. Z. , O'Quigley , J. ( 1996 ). Consistency of continual reassessment method in dose finding studies . Biometrika 83 : 395 – 406 .
   Web of Science ®Google Scholar
• Thall , P. F. , Cook , J. D. ( 2004 ). Dose-finding based on efficacy-toxicity trade-offs . Biometrics 60 : 684 – 693 .
   PubMed Web of Science ®Google Scholar
• Yin , G. , Li , Y. , Ji , Y. ( 2006 ). Bayesian dose-finding in Phase I/II clinical trials using toxicity and efficacy odds ratio . Biometrics 62 ( 3 ): 777 – 784 .
   PubMed Web of Science ®Google Scholar
• Zhou , J. , Shen , X. , Huang , J. , Hodes , R. J. , Rosenberg , S. A. , Robbins , P. F. ( 2005 ). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy . Journal of Immunology 175 ( 10 ): 7046 – 7052 .
   PubMed Web of Science ®Google Scholar